Clinical Trials Browser

Completed × INDUSTRY × Fulvestrant × Clear all

HR-positive, HER2-negative Advanced Breast Cancer

Multiple Endocrine Neoplasia Type 1

Neoplasm Metastasis, Neoplasms

Advanced Metastatic Breast Cancer

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Neoplasms

Breast Neoplasms

Breast Neoplasms, Neoplasms, Multiple Endocrine Neoplasia Type 1

Hormone Receptor Positive Breast Cancer

Breast Neoplasms

Advanced Cancer

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

Breast Neoplasms

Breast Neoplasms

Lethal Congenital Contracture Syndrome 2

Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site, Multiple Endocrine Neoplasia Type 1

Breast Neoplasms, Neoplasm Metastasis

Breast Neoplasms

Breast Neoplasms, Pancreatic Neoplasms, Small Cell Lung Carcinoma

Breast Neoplasms

Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer

Breast Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Neoplasm Metastasis, Multiple Endocrine Neoplasia Type 1

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

Mesothelioma, Malignant, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lymphoma, Lymphoma, Non-Hodgkin, Mesothelioma, Neoplasm Metastasis

Breast Neoplasms

Breast Neoplasms

Advanced Solid Tumors With an Alteration of the PIK3CA Gene

Breast Neoplasms, Neoplasm Metastasis

Postmenopausal Women With ER+ HER2- Primary Breast Cancer

Breast Neoplasms, Neoplasms

Breast Neoplasms

Breast Neoplasms, Neoplasms

Breast Neoplasms

Breast Neoplasms

Solid Malignancies

Clinical Trials

A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer

ALPINIST

FALCON

AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer

SPEAR

Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

BYLieve

SUMIT-BC

Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies

MORPHEUS HR+BC

EMERALD

A Study to Understand About the Study Medicine Palbociclib in Breast Cancer Patients After it is Out in the Japanese Market

A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer

B-PRECISE-01

This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer

First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors

SOLAR-1

monarcHER

GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer

A Phase 1 Study of LY2835219 In Participants With Advanced Cancer

BioItaLEE

PASTOR

PALOMA-3

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

MONALEESA-3

A Study of Abemaciclib in Indian Women With Advanced Breast Cancer

A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors

Open Label, Sequential Dosing , Single Ascending Dose and Multiple Dose Safety Tolerability and Pharmacokinetic Study

A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer

Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib Combinations for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2 ) Advanced/Metastatic Breast Cancer in the Arabian Gulf Region

INGE-B

Treat ER+ight

Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer

Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy

RIBBIT

A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer

A Study of LY3023414 in Participants With Advanced Cancer

A Single Arm, Tolerability and Safety Phase IV Study of Fulvestrant(Faslodex® ) as 2nd Line and Later Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer

Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer

A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene

BELLE-2

D6090C00002

FINDER II

Enzastaurin Plus Fulvestrant vs. Placebo Plus Fulvestrant in Breast Cancer

FIRST

STEM

Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer

14C